Hughes I W, Lustman F
Curr Med Res Opin. 1990;12(3):151-9. doi: 10.1185/03007999009111496.
Two hundred and thirty-three patients (66 males and 167 females), aged 24 to 92 years, with congestive cardiac failure were entered into a long-term study to evaluate the efficacy and tolerability of treatment with a fixed dose combination tablet containing 1 mg bumetanide and 5 mg amiloride. One hundred and fifty-five patients were treated for 52 weeks. The daily dosages were 1 tablet (113 patients), 2 tablets (35 patients), 3 or 4 tablets (7 patients). Treatment was associated with a marked reduction in the prevalence of ankle oedema, dyspnoea and pulmonary crepitations, and with statistically significant decreases in body weight, pulse rate and calf measurement. Mean serum potassium showed a small but statistically significant increase, but serious hyperkalaemia was not encountered. Although serum sodium decreased, serious hyponatraemia did not occur. No clinically significant effects on hepatic, renal or haemopoietic function were observed. Minor adverse effects, most of which resolved spontaneously, were reported by 60 patients. Only 14 (6.0%) patients ceased treatment because of adverse effects.
233例（男性66例，女性167例）年龄在24至92岁之间的充血性心力衰竭患者进入一项长期研究，以评估含有1毫克布美他尼和5毫克阿米洛利的固定剂量复方片剂治疗的疗效和耐受性。155例患者接受了52周的治疗。每日剂量为1片（113例患者）、2片（35例患者）、3或4片（7例患者）。治疗使踝部水肿、呼吸困难和肺部啰音的发生率显著降低，体重、脉搏率和小腿围度有统计学意义的下降。平均血清钾有小幅但有统计学意义的升高，但未出现严重高钾血症。虽然血清钠降低，但未发生严重低钠血症。未观察到对肝、肾或造血功能有临床显著影响。60例患者报告了轻微不良反应，其中大多数自行缓解。只有14例（6.0%）患者因不良反应停止治疗。
